IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
24 avr. 2024 08h00 HE
|
IN8bio, Inc
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
16 avr. 2024 16h05 HE
|
IN8bio, Inc
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
09 avr. 2024 16h30 HE
|
IN8bio, Inc
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
14 mars 2024 16h00 HE
|
IN8bio, Inc
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
05 mars 2024 16h30 HE
|
IN8bio, Inc
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
14 févr. 2024 08h00 HE
|
IN8bio, Inc
NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced a...
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals
04 janv. 2024 08h00 HE
|
IN8bio, Inc
Presented positive data showing continued durable complete remissions (CR) achieved in 100% of evaluable leukemia patients in Phase 1 investigator-sponsored trial of INB-100 at the 65th American...
IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia
11 déc. 2023 16h05 HE
|
IN8bio, Inc
Durable complete remission (CR) achieved in 100% of treated patients, including high-risk and relapsed acute myeloid leukemia (AML) patients and those who had failed multiple prior lines of therapy,...
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement
11 déc. 2023 09h00 HE
|
IN8bio, Inc
Initial closing of $14.4 million to support operational execution and extend cash runway into 2025 with potential for up to $32.5 million in additional capital at increasing valuations Proceeds to...
IN8bio Appoints Dr. Corinne Epperly to Board of Directors
07 déc. 2023 08h00 HE
|
IN8bio, Inc
Internationally recognized immuno-oncology and cell therapy executive with 20 years of experience in innovative immunotherapies for solid and hematological cancersBoard-Certified physician-scientist...